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been shown to improve disease-free and overall sur-
vivals. The benefits have been directly related to the
degree of clinical response to chemotherapy and to sub-
sequent complete surgical resection.2,3 The most effec-
tive combined treatment regimens for NSCLC are
based on cisplatin and induce a relevant clinical
response in about 50% of patients.4,5 Thus about half of
these patients do not benefit oncologically; they do not
achieve remission, nor are they able to undergo radical
resection after induction treatment. Predictive markers
will therefore have major implications for clinical treat-
ment in upcoming randomized trials.
TP53 gene alterations are present in about 50% of
NSCLCs, and their prognostic implications have been
evaluated in diverse clinical studies.6,7 Tumor response
to anticancer therapies has been recognized to be large-
ly based on apoptosis induction. Active p53 has emerged
as an important modulator of DNA damage–induced
apoptosis.8 A mutated TP53 gene could be related to
resistance to ionizing radiation and DNA-damaging
A pproximately 40% of patients with non–small celllung cancer (NSCLC) are initially seen with a local-
ly advanced stage of disease (stage III). Even if the
tumors are surgically accessible (stage IIIA), survival
among patients with advanced disease is poor (5-year
survival 5%-10%).1 Preoperative chemotherapy has
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agents, including etoposide and cisplatin, in vitro.9,10
Overexpression of p53 was shown to be linked to an
absence of pathologic response in patients with locally
advanced NSCLC.11 However, the absence of immuno-
staining did not necessarily correlate with a response to
cisplatin-based chemotherapy in that study. Thus im-
munostaining does not appear to be reliable as a predic-
tor of response to treatment.
Our study was designed to determine the value of
TP53 genotype for the prediction of chemotherapy
response. Because this phenomenon is evaluated on the
molecular genetic level, the potential failures of
immunohistochemistry are avoided. This article reports
the correlation between TP53 genotype and response to
cisplatin-based induction chemotherapy, as well as the
correlation with overall survival, among patients with
advanced NSCLC (stage IIIA or IIIB). Additionally, we
found no association between p53 immunohistochemi-
cal characteristics and TP53 genotype, which explains
the absence of a correlation between p53 immunohisto-
chemical results and response.
Materials and methods
The study included patients with stage IIIA and IIIB
NSCLC after cisplatin-based induction treatment. Patients
eligible for the study were those who, between 1995 and
1997, had undergone subsequent surgical resection or thora-
cotomy with biopsy after induction treatment. These criteria
were selected to enable histopathologic confirmation of
response to chemotherapy. Our study therefore does not
reflect the response rates observed in randomized studies; it
included more patients with responses to chemotherapy than
with resistance.
Patients’ cancers were staged by mediastinoscopy before
chemotherapy. Chemotherapy was administered intravenously
and consisted of cisplatin (30 mg/m2) in combination with ifos-
famide (1 g/m2), both administered from days 1 to 3 and
repeated every 28 days for a total of 3 cycles. Clinical response
was assessed by radiography and confirmed by histopatho-
logic studies. Patients with complete or partial remission
according to Union Internationale Contre le Cancer criteria
were considered to be responders, whereas those with stable or
progressive disease were considered to be nonresponders.
Statistical methods. Patients whose disease responded to
chemotherapy were compared with those whose disease was
resistant to chemotherapy. Associations between chemothera-
py response and TP53 genotype as well as p53 immunohisto-
chemical results were tested with the Fisher exact test.
Sensitivity (the probability that normal TP53 genotype char-
acterizes responders) and specificity (the probability that
TP53 mutant characterizes nonresponders) and correspond-
ing 95% confidence intervals are given. Sensitivity and speci-
ficity were calculated for TP53 immunohistochemical results
in predicting mutant or wild type TP53 genotype. The
Kaplan-Meier estimation of survival time after neoadjuvant
therapy for TP53 wild type (corresponding to responders)
and TP53 mutant (corresponding to nonresponders) geno-
types were calculated, and a log-rank test was used to com-
pare the 2 groups.12,13
Tumor tissue samples for TP53 analysis and histologic
examination were obtained before chemotherapy was started.
Tissue for TP53 sequencing was snap frozen and stored in liq-
uid nitrogen until analysis. Total genomic tumor DNA was ex-
tracted with a standard phenol-chloroform extraction method.
Genomic DNA (500 ng) was amplified by polymerase
chain reaction (PCR) with TP53-specific 20-nucleotide
primers placed in the adjacent intron regions of exons 2 to 3,
4, 5, 6, 7, 8 to 9, 10, and 11, as previously described.14
The quality and quantity of amplified DNA were checked
on precast 4% to 20% acrylamide and bis-acrylamide gels
(Novex, San Diego, Calif). As a reference standard we used
pBR322 DNA-MspI digest (Clontech Lab Inc, Palo Alto,
Calif).
Enzymatic pretreatment of polymerase chain reaction
products. Before sequencing of PCR products, residual sin-
gle-stranded primers and remaining deoxynucleoside triphos-
phate were removed from the PCR mixture. We subjected a
2-m L volume of a PCR amplification product to a combina-
tion of exonuclease I and shrimp alkaline phosphatase
(United States Biochemical, Cleveland, Ohio) and incubated
at 37°C for 60 minutes, followed by 15 minutes of enzyme
inactivation at 72°C.
Sequencing. Pretreated PCR products were diluted 1:2 and
were directly sequenced with the Thermo Sequinase radiola-
beled terminator cycle sequencing kit (United States
Biochemical, Cleveland, Ohio), which provides 4 radioac-
tively labeled dideoxynucleotide terminators (guanine, ade-
nine, thymine, and cytosine). Because of linkage of radioac-
tive label and chain termination, only properly terminated
DNA chains are visible. A 5.5-m L volume of enzymatically
pretreated PCR product was finally added to the reaction mix.
Cycle sequencing for linear increase of the DNA product dur-
ing sequencing reaction was then performed as described in
the kit, with deoxyguanosine triphosphate for termination
master mix and phosphorus 33–labeled dideoxynucleotides.
The cycle sequencing program was identical with the primer-
specific PCR amplification program. The reaction was
stopped on ice by adding 4 m L of STOP solution, and sam-
ples were stored at –20°C until sequencing gels could be
loaded (eg, the next day). After the 8% acrylamide and bis-
acrylamide gels were run, the latter were dried at 70° in a vac-
uum drying apparatus and directly exposed to a film (Bio
Max MR; Kodak, New Haven, Conn).
Phosphorus 33 labels and the high sensitivity of the film
allowed overnight exposure. The obtained sequences were
almost free of background activity, without stop artifacts, and
were easy to read. Mutations were confirmed by complete
reanalysis.
The p53 immunohistochemical testing was performed
according to the method published by Rush and colleagues11
746 Kandioler-Eckersberger et al The Journal of Thoracic and
Cardiovascular Surgery
April 1999
with the monoclonal antibody pAb1801 (Oncogene,
Uniondale, NY). Microscopic examination for the p53 stain-
ing product was scored as follows: negative, fewer than 10%
of cells staining; positive, more than 10%.
Results
Table I shows TP53 genotype and p53 immunohisto-
chemical results, listed with preoperative stage and TN
classification, clinical response, type of resection, and
histopathologic stage, for 24 patients who had received
induction chemotherapy for stage III NSCLC.
Preoperative stages IIIA and IIIB were equally distrib-
uted in the 2 groups. There were no differences in his-
tologic subtype between the 2 groups. Altogether, 11
squamous cell carcinomas, 6 adenocarcinomas, 6
adenosquamous carcinomas, and 1 large cell carcinoma
were included. Sixteen patients had major responses
(complete or partial remission), whereas eight patients
had stable or progressive disease. Of 4 patients who
had complete clinical responses, 2 showed complete
pathologic remission (8%). The correlation between
TP53 genotype and response is shown in Table II. A
normal TP53 genotype was present in all 16 patients
who had major responses. A mutant TP53 gene was
found in 8 of 8 patients who had clinically stable dis-
ease (n = 5) or progressive disease (n = 3). No associa-
tion between p53 protein expression and TP53 geno-
type was found (Table II). Sensitivity and specificity of
p53 immunohistochemical testing in indicating TP53
genotype were as high as 75% and 35%, respectively.
Corresponding 95% confidence intervals were 34.91%
to 96.82% and 12.76% to 64.86%, showing a weak sen-
sitivity of p53 immunohistochemical testing in indicat-
ing mutant genotype and no specificity of immunohis-
tochemical testing in indicating wild type genotype.
In comparing response to chemotherapy and TP53
genotype, clear associations between normal TP53
genotype and chemotherapy response and between
mutant genotype and chemotherapy resistance were
observed (P < .001, Table II). Sensitivity and specifici-
ty of TP53 gene analysis to predict response and non-
response were high (both 100% for the small number
Table I. Clinical data of 24 neoadjuvantly treated patients with NSCLC with respect to TP53 genotype and p53 
immunohistochemical results
Preoperative
Case Genotype IHC Histologic type Stage TN
663 Wild type ND Adenocarcinoma IIIA T3 N1
856 Wild type ND Squamous cell IIIA T1 N2
231 Wild type 80 Adenocarcinoma IIIA T3 N1
184 Wild type <10 Squamous cell IIIA T3 N2
769 Wild type 80 Squamous cell IIIB T2 N3
151 Wild type 90 Squamous cell IIIA T2 N2
568 Wild type <10 Adenocarcinoma IIIB T3 N3
377 Wild type 90 Adenosquamous IIIA T1 N2 
402 Wild type 80 Squamous cell IIIA T3 N2
207 Wild type <10 Large cell IIIA T2 N2
423 Wild type 90 Squamous cell IIIB T2 N3
140 Wild type <10 Adenocarcinoma IIIB T2 N3
407 Wild type 70 Squamous cell IIIA T2 N2
528 Wild type 70 Adenocarcinoma IIIB T2 N3
108 Wild type 70 Adenosquamous IIIA T3 N0
267 Wild type <10 Squamous cell IIIA T3 N2
42 Mutant <10 Adenocarcinoma IIIA T2 N2
238 Mutant 70 Adenocarcinoma IIIA T3 N1
854 Mutant 30 Squamous cell IIIB T3 N3
855 Mutant 70 Squamous cell IIIB T4 N0
145 Mutant <10 Squamous cell IIIB T3 N2
641 Mutant >90 Adenocarcinoma IIIA T2 N2
777 Mutant 80 Squamous cell IIIA T2 N2
657 Mutant 30 Adenocarcinoma IIIA T3 N0
IHC, Immunohistochemical result; ND, not determined; CR, complete remission; R0, complete resection; PR, partial remission; R1, marginal resection; SD, stable 
disease; PD, progressive disease; R2, incomplete resection.
*Diffuse single tumor cells.
†No lymph nodes found.
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of patients included). The corresponding 95% confi-
dence intervals were 82.93% to 100% for sensitivity
and 68.77% to 100% for specificity (the wide ranges of
the confidence intervals resulted from the small num-
bers of patients).
Patients were followed up for a median of 27 months.
The 75% overall survival time was 28 months among
patients whose disease responded to chemotherapy and
who had no TP53 gene mutations, whereas it was 8
months in the group with unresponsive disease and
TP53 mutations. With respect to overall survival the
difference between patients with mutated and unmutat-
ed tumors was statistically significant (P = .027, Fig 1).
The sequence analysis of the TP53 mutation of
patient 855 is shown in Fig 2. All detected mutations
are characterized in Table III. The mutations affected
the highly conserved regions of the TP53 gene (exons
5-8) in addition to exons 4 and 10 of the TP53 gene.
Fourteen of 16 patients in the responder group and 2
of 8 patients in the nonresponder group (both with stage
IIIA disease) could undergo complete resection. Four of
8 patients in the nonresponder group had pleural carci-
nosis at the time of thoracotomy. Three patients in the
nonresponder group with stage IIIB disease underwent
thoracotomy to confirm the unresectability suspected on
the basis of computed tomographic imaging.
Discussion
Induction chemotherapy has been reported to
improve the prognosis of stage III disease in patients
with NSCLC.15-17 From 40% to 50% of patients do not
have a response to chemotherapy, however, and to date
we have not been able to predict before chemotherapy
which patients these will be. The TP53 mutation fre-
quency has been reported to be as high as 50% in
NSCLC.18 In vitro a correlation between p53 status of
tumor cell lines and apoptosis induction in response to
cytotoxic treatment has been suggested.19 Until now,
however, no investigation successfully elucidated a
possible clinical association between response to
chemotherapy and the presence or absence of a normal
TP53 gene. In a clinical evaluation of patients with
NSCLC, Rush and associates11 found p53 protein over-
expression to be linked to the absence of pathologic
response in patients with locally advanced NSCLC,
whereas the absence of immunostaining did not neces-
Clinical response pTN Grading Operation Resection
CR T0 N0 x Extended pneumonectomy R0
CR T0 N0 2-3 Lobectomy R0
CR Tx* N0 x Pneumonectomy R0
CR T1 N0 x Pneumonectomy R0
PR T2 N2 2 Pneumonectomy R0
PR T0 N1 2 Lobectomy R0
PR T3 N0 2 Extended pneumonectomy R0
PR T1 N1 3 Bilobectomy R0
PR T1 N2 2-3 Lobectomy R0
PR T2 N0 3 Lobectomy R0
PR T2 N0 1-2 Lobectomy plus vascular sleeve R0
PR T2 N1 2 Pneumonectomy R1
PR T2 N1 2 Extended pneumonectomy R1
PR T2 Nx† 2-3 Lobectomy R0
PR T2 N0 3 Lobectomy R0
PR T2 N0 2 Pneumonectomy R0
SD T2 N2 3 Pneumonectomy R0
SD T4 N1 1-2 Extended pneumonectomy R1
SD T4 N3 2-3 Biopsy Biopsy only
SD T4 N0 2-3 Biopsy Biopsy only
SD T4 N2 3 Biopsy Biopsy only
PD T4 N2 2 Biopsy Biopsy only
PD T3 N2 3 Sleeve resection R0
PD T4 N0 2 Lobectomy R2
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sarily correlate with a response to cisplatin-based
chemotherapy in that study. This is exactly what we
found when we looked at p53 immunohistochemical
results and response in our patients—p53 overexpres-
sion was present in 6 of 8 tumors in the nonresponder
group but also in 9 of 16 tumors that did respond to
chemotherapy. When we analyzed the TP53 genotype,
however, we found a direct link both between mutant
genotype and resistance and between normal genotype
and response.
Ever since p53 immunohistochemical staining was
introduced, it has commonly been used as a fast and
easy method. However, the interpretation of staining
results remains a controversial subject.20,21 For exam-
ple, deletion and insertion mutations result in trunca-
tion of the p53 messenger RNA. Truncated messenger
RNA most probably will not be processed into a p53
protein, resulting in a negative immunostaining result
despite the presence of a functionally important muta-
tion. Currently available p53 antibodies mainly detect
overexpression of p53 protein on the basis of protein
stabilization, which is mainly due to point mutation. In
addition, p53 overexpression also has been shown to
result from TP53 gene activation and a high translation
rate in response to DNA damage, without the presence
of a mutation in the gene. High levels of p53 protein
therefore may also indicate the gene’s functional effort
to arrest cell cycling or to initiate apoptosis in cells that
are potentially malignant.
Our study shows for the first time that exact predic-
tive information concerning response to cisplatin-based
neoadjuvant chemotherapy in patients with NSCLC
can be obtained from TP53 genotype but not from p53
immunohistochemical staining. The abilities of DNA
sequencing and immunohistochemical testing to detect
mutations in the TP53 gene were compared in a study
on 316 patients with breast cancer. Immunohisto-
chemical testing was found to produce false-negative
results in 33% of cases and false-positive results in
30%.22 In addition, TP53 sequencing data yielded bet-
ter prognostic information in the reported cohort of
patients with breast cancer. In our study the major end
point was treatment response, not survival. Because we
found a 100% correlation of response with TP53 geno-
type, however, we correlated survival and TP53 geno-
type to determine whether the established link between
survival and response would hold true for our patients.
We think that the significant survival advantage we
Fig 2. Sequencing analysis showing part of exon 7 of the
TP53 gene from normal and tumor DNA of patient 855 (with
NSCLC unresponsive to cisplatin-based therapy). Tumor
sequence shows mutation in codon 248, a cytosine to thymine
transition (arrow).
Table II. Correlations between TP53 genotype and
chemotherapy response and between TP53 genotype
and p53 immunohistochemical result
Genotype
Mutant Wild type
Response
Complete or partial remission 0 16
Stable or progressive disease 8 0
Immunohistochemical result
Positive 5 9
Negative 3 5
Fig 1. Kaplan-Meier estimation of survival in patients with
and without TP53 mutations. A significant survival advantage
was found for patients with normal TP53 genotype. Patients
with normal TP53 genotype were found to correspond to
those with treatment response.
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found in the group with a normal TP53 genotype addi-
tionally confirms our conclusions.
The direct correlation we found between TP53 geno-
type and chemotherapy responsiveness may appear sur-
prising, because our study did not deal with other
mechanisms of apoptosis induction. However, the most
frequent genetic abnormalities in NSCLC are TP53 and
ras mutations, with mutation rates of 50% and 30%,
respectively.23 Rosell and colleagues2 found no rela-
tionship between good response and the absence or
presence of K-ras mutations, whereas Kishimoto and
associates6 found that TP53 mutations and K-ras muta-
tions occurred independently in primary NSCLC. Al-
though c-myc mutations are rarely seen in NSCLC,
other cell cycle–affecting proteins and tumor suppres-
sor genes appear to be, at least in part, under the con-
trol of TP53.23 TP53 may be essential for the pathway
of DNA damage–induced apoptosis that is important
for the cytotoxic effects of cisplatin and anthracyclins.
In our study the observed TP53 mutation frequency
was 33%, compared with 55% in unselected cases of
NSCLC. Because we wanted histopathologic confirma-
tion of clinical response, we included twice as many
patients undergoing surgery for response to chemother-
apy than patients undergoing surgery despite resistance
to chemotherapy (in a randomized trial, one would
expect at least 50% not to have a response). The lower
mutation frequency was therefore exactly as expected
and additionally underlines our findings.
In locally advanced NSCLC a favorable prognosis is
linked to response to induction treatment. Because of
response rates, however, half of these patients undergo
a toxic and expensive treatment without any benefit for
survival or quality of life. Some patients (with stage
IIIA disease) may even miss the chance of resection
because of progression during the course of treatment,
whereas optimal response to chemotherapy could result
in radical resection of primarily inoperable tumors
(stage IIIB). Limitation of induction treatment to
patients who are likely to respond should therefore be
the goal. We found that response to neoadjuvant thera-
py based on cisplatin and ifosfamide was directly relat-
ed to a normal TP53 genotype, for the first time pro-
viding clinical evidence of the TP53 dependent
cytotoxicity of these substances. Before TP53 geno-
type is introduced as a marker for possibly predicting
clinical response of NSCLC to neoadjuvant treatment,
however, this marker needs to be confirmed in a larger
prospective, randomized trial and needs to be tested for
other standard therapies.
We thank Jenny Hirsch for her assistance in preparing the
manuscript.
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